CPRX News and Press, Catalyst Pharmaceuticals Inc. From 12/16/22

Tesla stock might've made investors rich over the last few years, gaining more than 599.9% since late 2019, but 2022 has been a rough year for the company, with its shares losing slightly more than half their value amid a punishing bear market. In contrast, a little-known biotech called Catal...

Summary Catalyst Pharmaceuticals is in the process of entering new markets for its drug, Firdapse. It's also generating plenty of cash to spend on generating more growth. The lack of projects in the pipeline is the biggest long-term risk to watch. With its shares del...

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer ...

Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q3 Non-GAAP EPS of $0.26 beats by $0.07 . Revenue of $57.24M (+59.2% Y/Y) beats by $3.55M . FY2022 Guidance : The company has increased its forecast for total revenues to be in the range of betwe...

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ($0.22 per basic and $0.20 per diluted share), which Includes a ...

CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors looking for the best stocks to buy on a dip, “the dip” can mean a lot of different things. It can be the case of a market dominator that is trading near its low following a brutal bear market. Or...

CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...

The market may be down 23% this year, but that hasn't stopped a trio of drug companies from powering onward. Vertex Pharmaceuticals , (NASDAQ: VRTX) Catalyst Pharmaceuticals , (NASDAQ: CPRX) and Corcept Therapeutics (NASDAQ: CORT) are all rising sharply in contrast t...

CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announc...